Cargando…

Expression signature of the Leigh syndrome French-Canadian type

As a result of a founder effect, a Leigh syndrome variant called Leigh syndrome, French-Canadian type (LSFC, MIM / 220,111) is more frequent in Saguenay–Lac-Saint-Jean (SLSJ), a geographically isolated region on northeastern Quebec, Canada. LSFC is a rare autosomal recessive mitochondrial neurodegen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bchetnia, Mbarka, Tardif, Jessica, Morin, Charles, Laprise, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856909/
https://www.ncbi.nlm.nih.gov/pubmed/35242578
http://dx.doi.org/10.1016/j.ymgmr.2022.100847
_version_ 1784653942990307328
author Bchetnia, Mbarka
Tardif, Jessica
Morin, Charles
Laprise, Catherine
author_facet Bchetnia, Mbarka
Tardif, Jessica
Morin, Charles
Laprise, Catherine
author_sort Bchetnia, Mbarka
collection PubMed
description As a result of a founder effect, a Leigh syndrome variant called Leigh syndrome, French-Canadian type (LSFC, MIM / 220,111) is more frequent in Saguenay–Lac-Saint-Jean (SLSJ), a geographically isolated region on northeastern Quebec, Canada. LSFC is a rare autosomal recessive mitochondrial neurodegenerative disorder due to damage in mitochondrial energy production. LSFC is caused by pathogenic variants in the nuclear gene leucine-rich pentatricopeptide repeat-containing (LRPPRC). Despite progress understanding the molecular mode of action of LRPPRC gene, there is no treatment for this disease. The present study aims to identify the biological pathways altered in the LSFC disorder through microarray-based transcriptomic profile analysis of twelve LSFC cell lines compared to twelve healthy ones, followed by gene ontology (GO) and pathway analyses. A set of 84 significantly differentially expressed genes were obtained (p ≥ 0.05; Fold change (Flc) ≥ 1.5). 45 genes were more expressed (53.57%) in LSFC cell lines compared to controls and 39 (46.43%) had lower expression levels. Gene ontology analysis highlighted altered expression of genes involved in the mitochondrial respiratory chain and energy production, glucose and lipids metabolism, oncogenesis, inflammation and immune response, cell growth and apoptosis, transcription, and signal transduction. Considering the metabolic nature of LSFC disease, genes included in the mitochondrial respiratory chain and energy production cluster stood out as the most important ones to be involved in LSFC mitochondrial disorder. In addition, the protein-protein interaction network indicated a strong interaction between the genes included in this cluster. The mitochondrial gene NDUFA4L2 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, 4-like 2), with higher expression in LSFC cells, represents a target for functional studies to explain the role of this gene in LSFC disease. This work provides, for the first time, the LSFC gene expression profile in fibroblasts isolated from affected individuals. This represents a valuable resource to understand the pathogenic basis and consequences of LRPPRC dysfunction.
format Online
Article
Text
id pubmed-8856909
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88569092022-03-02 Expression signature of the Leigh syndrome French-Canadian type Bchetnia, Mbarka Tardif, Jessica Morin, Charles Laprise, Catherine Mol Genet Metab Rep Research Paper As a result of a founder effect, a Leigh syndrome variant called Leigh syndrome, French-Canadian type (LSFC, MIM / 220,111) is more frequent in Saguenay–Lac-Saint-Jean (SLSJ), a geographically isolated region on northeastern Quebec, Canada. LSFC is a rare autosomal recessive mitochondrial neurodegenerative disorder due to damage in mitochondrial energy production. LSFC is caused by pathogenic variants in the nuclear gene leucine-rich pentatricopeptide repeat-containing (LRPPRC). Despite progress understanding the molecular mode of action of LRPPRC gene, there is no treatment for this disease. The present study aims to identify the biological pathways altered in the LSFC disorder through microarray-based transcriptomic profile analysis of twelve LSFC cell lines compared to twelve healthy ones, followed by gene ontology (GO) and pathway analyses. A set of 84 significantly differentially expressed genes were obtained (p ≥ 0.05; Fold change (Flc) ≥ 1.5). 45 genes were more expressed (53.57%) in LSFC cell lines compared to controls and 39 (46.43%) had lower expression levels. Gene ontology analysis highlighted altered expression of genes involved in the mitochondrial respiratory chain and energy production, glucose and lipids metabolism, oncogenesis, inflammation and immune response, cell growth and apoptosis, transcription, and signal transduction. Considering the metabolic nature of LSFC disease, genes included in the mitochondrial respiratory chain and energy production cluster stood out as the most important ones to be involved in LSFC mitochondrial disorder. In addition, the protein-protein interaction network indicated a strong interaction between the genes included in this cluster. The mitochondrial gene NDUFA4L2 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, 4-like 2), with higher expression in LSFC cells, represents a target for functional studies to explain the role of this gene in LSFC disease. This work provides, for the first time, the LSFC gene expression profile in fibroblasts isolated from affected individuals. This represents a valuable resource to understand the pathogenic basis and consequences of LRPPRC dysfunction. Elsevier 2022-02-05 /pmc/articles/PMC8856909/ /pubmed/35242578 http://dx.doi.org/10.1016/j.ymgmr.2022.100847 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Bchetnia, Mbarka
Tardif, Jessica
Morin, Charles
Laprise, Catherine
Expression signature of the Leigh syndrome French-Canadian type
title Expression signature of the Leigh syndrome French-Canadian type
title_full Expression signature of the Leigh syndrome French-Canadian type
title_fullStr Expression signature of the Leigh syndrome French-Canadian type
title_full_unstemmed Expression signature of the Leigh syndrome French-Canadian type
title_short Expression signature of the Leigh syndrome French-Canadian type
title_sort expression signature of the leigh syndrome french-canadian type
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856909/
https://www.ncbi.nlm.nih.gov/pubmed/35242578
http://dx.doi.org/10.1016/j.ymgmr.2022.100847
work_keys_str_mv AT bchetniambarka expressionsignatureoftheleighsyndromefrenchcanadiantype
AT tardifjessica expressionsignatureoftheleighsyndromefrenchcanadiantype
AT morincharles expressionsignatureoftheleighsyndromefrenchcanadiantype
AT laprisecatherine expressionsignatureoftheleighsyndromefrenchcanadiantype